EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2025
Atrial fibrillation (AF) is a disorder of the heart’s conduction system. The condition is characterized by an irregular heart rhythm that is either too fast or too slow. During AF, the two upper chambers of the heart (atria) beat out of coordination with the two lower chambers (ventricles) due to disorganized electrical signals. Consequently, the blood doesn’t flow as well as it should from the atria to the ventricles, resulting in poor blood supply to the rest of the body. AF symptoms typically include heart palpitations, chest discomfort, shortness of breath, dizziness, and weakness (CDC, 2015; Mayo Clinic, 2016; NHLBI, 2014). However, individuals with AF may be asymptomatic and not even know that they have the condition until it is identified through an electrocardiogram (ECG) test.
In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of AF will increase from 9,487,217 cases in 2015 to 11,536,773 cases in 2025, at an Annual Growth Rate (AGR) of 2.16%. The US will have the highest number of diagnosed prevalent cases of AF among the 8MM throughout the forecast period, while Canada will have the lowest. In the 8MM, permanent AF is forecast to be the predominant subtype of AF. In the US, Germany, Spain, the UK, Japan, and Canada, paroxysmal AF is forecast to be the second most predominant subtype, while persistent AF is the second most common subtype in France and Italy.
Reasons to buy
- The Atrial fibrillation (AF) EpiCast Report is an overview of the risk factors, comorbidities, and the global and historical trends for AF in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AF based on country-specific studies published in peer-reviewed journals. The diagnosed prevalent cases of AF are segmented by age (at 5-year intervals, starting at age 40 years), sex, and clinical subtypes (paroxysmal, persistent, and permanent AF) in the 8MM.
- The AF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
The AF EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global AF market.
- Quantify patient populations in the global AF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AF therapeutics in each of the markets covered.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Epidemiology
- 2.1 Risk Factors and Comorbidities
- 2.2 Global Trends
- 2.3 Forecast Methodology
- 2.3.1 Sources Used
- 2.3.2 Forecast Assumptions and Methods
- 2.3.3 Sources Not Used
- 2.4 Epidemiological Forecast for AF (2015-2025)
- 2.4.1 Diagnosed Prevalent Cases
- 2.5 Discussion
- 2.5.1 Epidemiological Forecast Insight
- 2.5.2 Limitations of the Analysis
- 2.5.3 Strengths of the Analysis
- 3 Appendix
- 3.1 Bibliography
- 3.2 About the Authors
- 3.2.1 Epidemiologist
- 3.2.2 Reviewers
- 3.2.3 Global Director of Therapy Analysis and Epidemiology
- 3.2.4 Global Head of Healthcare
- 3.3 About GlobalData
- 3.4 About EpiCast
- 3.5 Disclaimer
- 1.1 List of Tables
- Table 1: Clinical Subtypes of AF
- Table 2: Risk Factors and Comorbidities for AF
- Table 3: Prevalence (%) of AF as Reported in Epidemiological Studies
- Table 4: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AF
- Table 5: 8MM, Sources Used to Forecast Clinical Subtypes of Diagnosed Prevalent Cases of AF
- Table 6: 8MM, Sources Not Used in the Epidemiological Analysis of AF
- Table 7: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, Selected Years 2015-2025
- Table 8: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N (Row %), 2015
- Table 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, N (Row %), 2015
- 1.2 List of Figures
- Figure 1: 8MM, Diagnosed Prevalent Cases of AF, Ages ≥40 Years, Both Sexes, N, 2015-2025
- Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of AF, Both Sexes, N, 2015
- Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of AF, Ages ≥40 Years, 2015
- Figure 4: 8MM, Age-Standardized Diagnosed Prevalence of AF, Ages ≥40 Years, N, 2015
- Figure 5: 8MM, Diagnosed Prevalent Cases of AF by Clinical Subtypes, Both Sexes, Ages ≥40 Years, 2015